A Single-center, Prospective, Self-controlled, Observational Real-world Study of the Efficacy and Safety of Anti-IL-17A/F Monoclonal Antibody Combined With Non-ablative Dot Laser for the Treatment of Mild to Moderate Hidradenitis Suppurativa

Inclusion criteria

• Patients voluntarily participate in the study and sign the informed consent form.
• Male or female participants aged ≥ 18 years (at the time of signing the informed consent form).
• Patients with mild to moderate hidradenitis suppurativa: Hurley stage I or II.
• Participants have stable disease at screening and baseline, with lesions in ≥ 1 anatomical region and a total abscess and inflammatory nodule (AN) count ≥ 3.
• Participants must have intolerance, contraindication, or inadequate response to oral antibiotic treatment for HS for at least 3 months, or have relapsed after stopping such treatment.
• Have a basic understanding of the study purpose, the intervention, and possible side effects, and voluntarily sign the informed consent form in accordance with the spirit of the Declaration of Helsinki.
• Agree to receive regular treatment, attend follow-up visits, and undergo the required examinations and tests as specified in the clinical study protocol.

Exclusion criteria

• Known allergy to the study drug or its excipients.
• Prior use of biologics or small molecule targeted agents.
• Presence of tunnels on ultrasound at baseline; diagnosed with inflammatory diseases other than HS; history of chronic or recurrent infections; history of malignancy.
• History of drug abuse, suicide attempt, or psychiatric disorders.
• Participated in another clinical trial within the past 3 months.
• Pregnant or breastfeeding women, or those planning to become pregnant during the study period.
• Any other condition that, in the opinion of the investigator, would make the participant unsuitable for inclusion.
• Systemic use of corticosteroids within the past 4 weeks, or topical use within the past 2 weeks.